CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$44.65 USD
-1.09 (-2.38%)
Updated Mar 20, 2023 03:40 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRSP 44.65 -1.09(-2.38%)
Will CRSP be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges
CRISPR Therapeutics AG (CRSP) Stock Moves -0.51%: What You Should Know
Other News for CRSP
Crispr Therapeutics price target lowered to $55 from $63 at Citi
3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time
Crispr Therapeutics initiated with a Buy at Bryan Garnier
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
CRISPR Therapeutics Announces Transition of Chief Financial Officer